目的 探討銀丹心腦通軟膠囊聯(lián)合注射用纖溶酶治療腦梗死的臨床療效。方法 選取2013年10月-2015年6月天津市北辰醫(yī)院收治的腦梗死患者80例，按照隨機數(shù)字表法隨機分為對照組和治療組，每組各40例。對照組靜脈滴注注射用纖溶酶，100 U加入到250 mL葡萄糖注射液中，滴注速度50滴/min，1次/d。治療組在對照組基礎(chǔ)上口服銀丹心腦通軟膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療12 d。觀察兩組的臨床療效，比較兩組美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、Barthel指數(shù)（BI）評分、血液流變學(xué)指標情況。結(jié)果 治療后，對照組和治療組的總有效率分別為67.5%、87.5%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組NIHSS評分均顯著下降，BI評分均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組全血黏度、血漿黏度和血小板聚集率均顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 銀丹心腦通軟膠囊聯(lián)合注射用纖溶酶治療腦梗死具有較好的臨床療效，能改善神經(jīng)功能，提高生活自理能力，改善血液流變學(xué)指標，具有一定的臨床推廣應(yīng)用價值。

Objective To study the clinical effects of Yindan Xinnaotong Soft Capsules combined with Fibrinogenase for injection in treatment of cerebral infarction. Methods Patients (80 cases) with cerebral infarction in Tianjin Beichen Hospital from October 2013 to June 2015 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Fibrinogenase for injection, 100 U added into glucose solution 250 mL, 50 drops/min, once daily. Patients in the treatment group were po administered with B Yindan Xinnaotong Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores, BI scores, and blood rheology indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 67.5% and 87.5%, respectively, and there was difference between two groups (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, but BI scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, whole blood viscosity, plasma viscosity, and platelet aggregation rate in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yindan Xinnaotong Soft Capsules combined with Fibrinogenase for injection has clinical curative effect in treatment of cerebral infarction, can improve nerve function, increase self-care ability, and Improve blood rheology index, which has a certain clinical application value.